UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 223

Sortiert nach

Pharmacological and genetic manipulations at the µ-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice

Neuropsychopharmacology (New York, N.Y.), 2021-12, Vol.46 (13), p.2241-2249

2021

Link zum Volltext

Verfügbarkeit prüfen

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma

Frontiers in oncology, 2022-11, Vol.12, p.1038329-1038329

2022

Link zum Volltext

Verfügbarkeit prüfen

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease

Nature communications, 2019-10, Vol.10 (1), p.4533-15, Article 4533

2019

Link zum Volltext

Verfügbarkeit prüfen

Hepcidin is regulated by promoter-associated histone acetylation and HDAC3

Nature communications, 2017-09, Vol.8 (1), p.403-15, Article 403

2017

Link zum Volltext

Verfügbarkeit prüfen

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

Frontiers in genetics, 2022-02, Vol.13, p.831779-831779

2022

Link zum Volltext

Verfügbarkeit prüfen

Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1 trial): study protocol for observational cohort study

BMJ open, 2022-04, Vol.12 (4), p.e057163-e057163

2022

Link zum Volltext

Verfügbarkeit prüfen

Set screw homogenization of murine ocular tissue, including the whole eye

Molecular vision, 2018-10, Vol.24, p.690-699

2018

Link zum Volltext

Verfügbarkeit prüfen

Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment

Scientific reports, 2019-10, Vol.9 (1), p.14189-11, Article 14189

2019

Link zum Volltext

Verfügbarkeit prüfen

P1362: DEVELOPMENT OF A NOVEL ONCOLYTIC VIRUS ‐THEO‐310 ‐ SPECIALISED FOR TARGETING THE BONE MARROW TUMOUR MICROENVIRONMENT OF MULTIPLE MYELOMA PATIENTS

HemaSphere, 2023-08, Vol.7 (S3), p.e334939c-n/a

2023

Link zum Volltext

Verfügbarkeit prüfen

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs

PloS one, 2015-09, Vol.10 (9), p.e0136207

2015

Link zum Volltext

Verfügbarkeit prüfen

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Blood cancer journal (New York), 2023-01, Vol.13 (1), p.12-12, Article 12

2023

Link zum Volltext

Verfügbarkeit prüfen

Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders

Journal of allergy and clinical immunology, 2015-08, Vol.136 (2), p.487-490.e2

2015

Link zum Volltext

Verfügbarkeit prüfen

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Blood cancer journal (New York), 2023-02, Vol.13 (1), p.24-24, Article 24

2023

Link zum Volltext

Verfügbarkeit prüfen

Role of bone morphogenetic protein signalling in bone destruction and niche maintenance in a mouse model of multiple myeloma

The Lancet (British edition), 2016-02, Vol.387, p.S47-S47

2016

Link zum Volltext

Verfügbarkeit prüfen

Validation of clinical‐grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly‐diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project

EJHaem, 2021-11, Vol.2 (4), p.809-812

2021

Link zum Volltext

Verfügbarkeit prüfen

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect

International journal of hematology, 2014-06, Vol.99 (6), p.798-800

2014

Link zum Volltext

Verfügbarkeit prüfen

A Balancing Act: Learning from the Past to Build a Future-Focused Opioid Strategy

Annual review of physiology, 2024-02, Vol.86, p.1

2024

Link zum Volltext

Verfügbarkeit prüfen

Gremlin 1 — small protein, big impact: the multiorgan consequences of disrupted BMP antagonism

The Journal of pathology, 2020-08, Vol.251 (4), p.349-352

2020

Link zum Volltext

Verfügbarkeit prüfen

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

Blood, 2021-01, Vol.137 (2), p.232-237

2021

Link zum Volltext

Verfügbarkeit prüfen

New approaches to targeting the bone marrow microenvironment in multiple myeloma

Current opinion in pharmacology, 2016-06, Vol.28, p.43-49

2016

Link zum Volltext

Verfügbarkeit prüfen

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Blood, 2022-11, Vol.140 (Supplement 1), p.12603-12604

2022

Link zum Volltext

Verfügbarkeit prüfen

Central Ontario

Forestry chronicle, 2012-06, Vol.88 (3), p.355-358

Gooding, Sarah

2012

Link zum Volltext

Verfügbarkeit prüfen

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

Blood, 2023-02, Vol.141 (6), p.620-633

2023

Link zum Volltext

Verfügbarkeit prüfen

COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

British journal of haematology, 2022-01, Vol.196 (1), p.95-98

2022

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 223

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(209)
Mit Volltextzugriff
(214)

Publikationsform

Sprache

Englisch
(223)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(154)
Life Sciences & Biomedicine
(103)
Humans
(74)
Physical Sciences
(43)
Chemistry
(37)
Female
(34)
Male
(33)
Adult
(31)
Technology
(29)
Middle Aged
(24)
Adolescent
(22)
Psychiatry
(21)
Young Adult
(21)
Aged
(18)
Materials Science
(18)
Chemistry, Multidisciplinary
(17)
Risk Factors
(17)
Science & Technology - Other Topics
(17)
Social Sciences
(16)
Suicide
(16)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Pharmacological and genetic manipulations at the µ-opioid receptor reveal arrestin-3 engagement limits analgesic tolerance and does not exacerbate respiratory depression in mice

Tumor and microenvironmental mechanisms of resistance to immunomodulatory drugs in multiple myeloma

Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease

Hepcidin is regulated by promoter-associated histone acetylation and HDAC3

Multiple Myeloma Patient Tumors With High Levels of Cereblon Exon-10 Deletion Splice Variant Upregulate Clinically Targetable Pro-Inflammatory Cytokine Pathways

Precision medicine for liver tumours with quantitative MRI and whole genome sequencing (Precision1 trial): study protocol for observational cohort study

Set screw homogenization of murine ocular tissue, including the whole eye

Multiple myeloma increases nerve growth factor and other pain-related markers through interactions with the bone microenvironment

Prospective Assessment of Tumour Burden and Bone Disease in Plasma Cell Dyscrasias Using DW-MRI and Exploratory Bone Biomarkers

P1362: DEVELOPMENT OF A NOVEL ONCOLYTIC VIRUS ‐THEO‐310 ‐ SPECIALISED FOR TARGETING THE BONE MARROW TUMOUR MICROENVIRONMENT OF MULTIPLE MYELOMA PATIENTS

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs

Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Key stages of bone marrow B-cell maturation are defective in patients with common variable immunodeficiency disorders

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma

Role of bone morphogenetic protein signalling in bone destruction and niche maintenance in a mouse model of multiple myeloma

Validation of clinical‐grade whole genome sequencing reproduces cytogenetic analysis and identifies mutational landscape in newly‐diagnosed multiple myeloma patients: A pilot study from the 100,000 Genomes Project

Gemcitabine-induced large vessel vasculitis demonstrated by PET CT: a rare, important side effect

A Balancing Act: Learning from the Past to Build a Future-Focused Opioid Strategy

Gremlin 1 — small protein, big impact: the multiorgan consequences of disrupted BMP antagonism

Multiple cereblon genetic changes are associated with acquired resistance to lenalidomide or pomalidomide in multiple myeloma

New approaches to targeting the bone marrow microenvironment in multiple myeloma

Artificial Intelligence-Based Quantitative and Topological Analysis of Plasma Cell Burden: A New Tool for the Assessment of Myeloma

Central Ontario

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma

COVID symptoms, testing, shielding impact on patient‐reported outcomes and early vaccine responses in individuals with multiple myeloma

Suchergebnisse filtern